BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16904114)

  • 21. Cytokine and hormonal profile in blood serum and follicular fluids during ovarian stimulation with the multidose antagonist or the long agonist protocol.
    Asimakopoulos B; Köster F; Felberbaum R; Al-Hasani S; Diedrich K; Nikolettos N
    Hum Reprod; 2006 Dec; 21(12):3091-5. PubMed ID: 17008327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
    Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
    Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escherichia coli derived factors modulate human granulosa cell steroidogenesis.
    Reinsberg J; Christoffel S; Kumar A; van der Ven H
    Acta Physiol Scand; 2005 Dec; 185(4):303-12. PubMed ID: 16266371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of GnRH antagonists and flareup GnRH agonists in donor oocyte cycles.
    Wei AY; Mijal KA; Christianson MS; Schouweiler CM; Lindheim SR
    J Reprod Med; 2008 Mar; 53(3):147-50. PubMed ID: 18441715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of phytoestrogen daidzein and estradiol on steroidogenesis and expression of estrogen receptors in porcine luteinized granulosa cells from large follicles.
    Nynca A; Jablonska O; Slomczynska M; Petroff BK; Ciereszko RE
    J Physiol Pharmacol; 2009 Jun; 60(2):95-105. PubMed ID: 19617652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Action of defined mixtures of PCBs, p,p'-DDT and its metabolite p,p'-DDE, on co-culture of porcine theca and granulosa cells: steroid secretion, cell proliferation and apoptosis.
    Gregoraszczuk EL; Ptak A; Karniewska M; Ropstad E
    Reprod Toxicol; 2008 Oct; 26(2):170-4. PubMed ID: 18692563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical application of GnRH antagonist to uterine fibroid].
    Ayabe T
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():116-21. PubMed ID: 16689295
    [No Abstract]   [Full Text] [Related]  

  • 28. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
    Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
    Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rate of aneuploidy in luteinized granulosa cells obtained from follicular fluid in women who underwent controlled ovarian hyperstimulation.
    Kaleli S; Yanikkaya-Demirel G; Erel CT; Senturk LM; Topçuoğlu A; Irez T
    Fertil Steril; 2005 Sep; 84(3):802-4. PubMed ID: 16169431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gómez R; Delgado-Rosas F; Cauli O; Simón C; Gaytán F; Pellicer A
    Fertil Steril; 2014 May; 101(5):1411-8. PubMed ID: 24581579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF.
    Manau D; Fábregues F; Peñarrubia J; Creus M; Carmona F; Casals G; Jiménez W; Balasch J
    Hum Reprod; 2007 Mar; 22(3):669-75. PubMed ID: 17079244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of gonadotropin-releasing hormone antagonists in poor responders.
    Mahutte NG; Arici A
    Fertil Steril; 2007 Feb; 87(2):241-9. PubMed ID: 17113088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells.
    Weiss JM; Oltmanns K; Gürke EM; Polack S; Eick F; Felberbaum R; Diedrich K; Ortmann O
    Eur J Endocrinol; 2001 Jun; 144(6):677-85. PubMed ID: 11375803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome.
    Rabinson J; Meltcer S; Zohav E; Gemer O; Anteby EY; Orvieto R
    Fertil Steril; 2008 Feb; 89(2):472-4. PubMed ID: 17582402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fisch JD; Keskintepe L; Sher G
    Fertil Steril; 2008 Feb; 89(2):342-7. PubMed ID: 17562336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential gonadotropin releasing hormone (GnRH) expression, autoregulation and effects in two models of rat luteinized ovarian cells.
    Sorianello EM; Fernandez MO; Catalano PN; Mongiat LA; Somoza GM; Libertun C; Lux-Lantos VA
    Life Sci; 2005 Sep; 77(17):2141-55. PubMed ID: 16005024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
    Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
    Artini PG; Monti M; Matteucci C; Valentino V; Cristello F; Genazzani AR
    Gynecol Endocrinol; 2006 Aug; 22(8):465-70. PubMed ID: 17012110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of vascular endothelial growth factor (VEGF) receptor in goat ovaries and improvement of in vitro caprine preantral follicle survival and growth with VEGF.
    Bruno JB; Celestino JJ; Lima-Verde IB; Lima LF; Matos MH; Araújo VR; Saraiva MV; Martins FS; Name KP; Campello CC; Báo SN; Silva JR; Figueiredo JR
    Reprod Fertil Dev; 2009; 21(5):679-87. PubMed ID: 19486605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.